CN Mobile Logo


Renal Cell Carcinoma

Renal Cell Carcinoma

Clinicians now have a new targeted therapy option for treating patients with advanced renal cell carcinoma (RCC) who have received prior antiangiogenic therapy.

The combination of the novel histone deacetylase inhibitor entinostat and high-dose interleukin-2 yielded a promising response rate in patients with metastatic renal cell carcinoma.

Progression-free survival in advanced renal cell carcinoma patients treated with cabozantinib was nearly doubled compared with those treated with everolimus, according to data from the METEOR trial.

A new study has confirmed the safety and efficacy of pazopanib in a real-world setting of patients with metastatic renal cell carcinoma (mRCC) and validates the International Metastatic Renal Cell Carcinoma Database (IMDC) prognostic model in this patient population.

Administering pharmacological prophylaxis against venous thromboembolism (VTE) did not decrease the occurrence of VTE in patients treated with robotic partial nephrectomy, and it did not increase the rate of hemorrhagic events.

The FDA has approved the anti–PD-1 immunotherapy nivolumab (Opdivo) for the treatment of metastatic renal cell carcinoma.

A 42-year-old man presented with increasing right hip pain that limited his ability to walk. Magnetic resonance imaging (MRI) revealed a right lytic acetabular lesion. Further work-up included a computed tomography (CT) scan, which revealed an 8-cm left kidney tumor.


Subscribe to Renal Cell Carcinoma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.